{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:51:47Z","timestamp":1782323507695,"version":"3.54.5"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2022R1G1A1006030"],"award-info":[{"award-number":["NRF-2022R1G1A1006030"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ICKSH Research Project of the Korean Society of Hematology","award":["ICKSH-2021-01"],"award-info":[{"award-number":["ICKSH-2021-01"]}]},{"DOI":"10.13039\/501100002642","name":"Korea University","doi-asserted-by":"crossref","award":["K2510551"],"award-info":[{"award-number":["K2510551"]}],"id":[{"id":"10.13039\/501100002642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Extracellular vesicle (EV)-derived microRNAs (miRNAs) represent a promising platform for biomarker discovery in acute lymphoblastic leukemia (ALL). This study evaluated the biomarker potential of EV-derived miRNAs isolated from five ALL cell lines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Human ALL cell lines were cultured in EV-depleted fetal bovine serum. These included two parental cell lines, CCL-119 and CRL-3273, and three related cell lines previously characterized as exhibiting chemoresistance-associated phenotypes: CRL-2264 and CRL-2265, derived from CCL-119, and CRL-3274, derived from CRL-3273. EVs were isolated using a commercial size-exclusion chromatography-based method and characterized by nanoparticle tracking analysis, transmission electron microscopy, and immunoblotting for CD9, CD63, and CD81. Small RNA sequencing was subsequently performed. All data processing and visualization were conducted using R statistical software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Across all samples, 2,656 EV-derived miRNAs were identified. Among these, three EV-derived miRNAs were prioritized based on consistent directional differences in this exploratory analysis: miR-1226-5p and miR-760 were downregulated, whereas miR-29b-3p was upregulated. To further assess their potential clinical relevance, we evaluated associations between survival and the expression of predicted target genes using the GSE5314 dataset. Higher expression of\n                      <jats:italic>AHI1<\/jats:italic>\n                      , a gene implicated in leukemogenesis and drug resistance and linked to downregulated miR-760 in our models, was associated with poor survival in patients with ALL.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This exploratory study identified three EV-derived miRNAs, miR-1226-5p, miR-760, and miR-29b-3p, together with the related gene\n                      <jats:italic>AHI1<\/jats:italic>\n                      , as candidate biomarker leads in ALL cell line models. Further validation using patient-derived EVs, plasma samples, and subtype-aware clinical cohorts is required before clinical interpretation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0352501","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:31:11Z","timestamp":1782322271000},"page":"e0352501","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential of extracellular vesicle-derived microRNAs as a platform for biomarker discovery in acute lymphoblastic leukemia"],"prefix":"10.1371","volume":"21","author":[{"given":"Jeong-An","family":"Gim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5908-2607","authenticated-orcid":true,"given":"Kunye","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1462-0502","authenticated-orcid":true,"given":"Ka-Won","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"issue":"4","key":"pone.0352501.ref001","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.hemonc.2017.05.015","article-title":"Hematopoietic cell transplantation for acute lymphoblastic leukemia in adult patients","volume":"10","author":"R El Fakih","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"2","key":"pone.0352501.ref002","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/ejh.13247","article-title":"Survival in adult acute lymphoblastic leukaemia (ALL): A report from the Swedish ALL Registry","volume":"103","author":"E Lennmyr","year":"2019","journal-title":"Eur J Haematol"},{"issue":"5","key":"pone.0352501.ref003","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/bjh.16242","article-title":"Outcomes of acute lymphoblastic leukaemia in adolescent and young adult Korean patients","volume":"188","author":"YA Kim","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"pone.0352501.ref004","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-023-01409-5","article-title":"The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades","volume":"16","author":"E Jabbour","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"5","key":"pone.0352501.ref005","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(23)00064-9","article-title":"Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past","volume":"10","author":"NJ Short","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"pone.0352501.ref006","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"E Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"issue":"3","key":"pone.0352501.ref007","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/j.seminhematol.2020.11.001","article-title":"Role of blinatumomab, inotuzumab, and CAR T-cells: Which to choose and how to sequence for patients with relapsed disease","volume":"57","author":"E Curran","year":"2020","journal-title":"Semin Hematol"},{"key":"pone.0352501.ref008","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood-2021-154022","article-title":"Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia","volume":"138","author":"NJ Short","year":"2021","journal-title":"Blood"},{"key":"pone.0352501.ref009","doi-asserted-by":"crossref","first-page":"7034","DOI":"10.1200\/JCO.2022.40.16_suppl.7034","article-title":"A phase II study of hyper-CVAD with sequential blinatumomab (Blina), with or without inotuzumab ozogamicin (INO), in adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL)","volume":"40","author":"NJ Short","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"pone.0352501.ref010","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3324\/haematol.2015.141101","article-title":"New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia","volume":"101","author":"AV Moorman","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"pone.0352501.ref011","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood.2019002220","article-title":"Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia","volume":"135","author":"B Li","year":"2020","journal-title":"Blood"},{"issue":"7","key":"pone.0352501.ref012","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/14737159.2019.1633307","article-title":"The potential of circulating cell free RNA as a biomarker in cancer","volume":"19","author":"KWE Cheung","year":"2019","journal-title":"Expert Rev Mol Diagn"},{"key":"pone.0352501.ref013","article-title":"Non-exosomal and exosomal circulatory microRNAs: which are more valid as biomarkers?","author":"NNSB Nik Mohamed Kamal","year":"2020","journal-title":"Frontiers in Pharmacology"},{"issue":"1","key":"pone.0352501.ref014","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41598-020-80514-8","article-title":"Dual size-exclusion chromatography for efficient isolation of extracellular vesicles from bone marrow derived human plasma","volume":"11","author":"J-H Jung","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"pone.0352501.ref015","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12404","article-title":"Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches","volume":"13","author":"JA Welsh","year":"2024","journal-title":"J Extracell Vesicles"},{"key":"pone.0352501.ref016","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.05005","article-title":"Predicting effective microRNA target sites in mammalian mRNAs","volume":"4","author":"V Agarwal","year":"2015","journal-title":"Elife"},{"key":"pone.0352501.ref017","doi-asserted-by":"crossref","first-page":"8941471","DOI":"10.1155\/2019\/8941471","article-title":"The Role of MicroRNA in Paediatric Acute Lymphoblastic Leukaemia: Challenges for Diagnosis and Therapy","volume":"2019","author":"C Grobbelaar","year":"2019","journal-title":"J Oncol"},{"key":"pone.0352501.ref018","first-page":"2903","article-title":"The functional role of microRNA in acute lymphoblastic leukemia: relevance for diagnosis, differential diagnosis, prognosis, and therapy","volume":"8","author":"C Luan","year":"2015","journal-title":"Onco Targets Ther"},{"issue":"4","key":"pone.0352501.ref019","first-page":"1104","article-title":"B-cell acute lymphoblastic leukemia-related microRNAs: uncovering their diverse and special roles","volume":"11","author":"M Lv","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"6","key":"pone.0352501.ref020","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.4161\/cc.9.6.11011","article-title":"A novel mutation in the miR-128b gene reduces miRNA processing and leads to glucocorticoid resistance of MLL-AF4 acute lymphocytic leukemia cells","volume":"9","author":"A Kotani","year":"2010","journal-title":"Cell Cycle"},{"issue":"10","key":"pone.0352501.ref021","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.3109\/10428194.2012.678004","article-title":"Involvement of miR17 pathway in glucocorticoid-induced cell death in pediatric acute lymphoblastic leukemia","volume":"53","author":"M Harada","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"pone.0352501.ref022","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/cas.12339","article-title":"Downregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors","volume":"105","author":"C Nishioka","year":"2014","journal-title":"Cancer Sci"},{"issue":"9","key":"pone.0352501.ref023","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/leu.2011.105","article-title":"Discovery of new microRNAs by small RNAome deep sequencing in childhood acute lymphoblastic leukemia","volume":"25","author":"D Schotte","year":"2011","journal-title":"Leukemia"},{"issue":"5","key":"pone.0352501.ref024","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3324\/haematol.2010.026138","article-title":"MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia","volume":"96","author":"D Schotte","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"pone.0352501.ref025","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s11033-019-04600-5","article-title":"Genome-wide identification of microRNA signatures associated with stem\/progenitor cells in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"46","author":"E Valiollahi","year":"2019","journal-title":"Mol Biol Rep"},{"issue":"11","key":"pone.0352501.ref026","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20192358","article-title":"MiR-760 enhances sensitivity of pancreatic cancer cells to gemcitabine through modulating Integrin \u03b21","volume":"39","author":"D Yang","year":"2019","journal-title":"Biosci Rep"},{"issue":"6","key":"pone.0352501.ref027","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1111\/jcmm.14071","article-title":"LncRNA KCNQ1OT1 enhanced the methotrexate resistance of colorectal cancer cells by regulating miR-760\/PPP1R1B via the cAMP signalling pathway","volume":"23","author":"D Xian","year":"2019","journal-title":"J Cell Mol Med"},{"key":"pone.0352501.ref028","first-page":"539","article-title":"The role of miR-29b in cancer: regulation, function, and signaling","volume":"8","author":"B Yan","year":"2015","journal-title":"Onco Targets Ther"},{"key":"pone.0352501.ref029","doi-asserted-by":"crossref","first-page":"173752","DOI":"10.1016\/j.ejphar.2020.173752","article-title":"Lnc NEAT1\/miR-29b-3p\/Sp1 form a positive feedback loop and modulate bortezomib resistance in human multiple myeloma cells","volume":"891","author":"F Che","year":"2021","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"pone.0352501.ref030","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.bbrc.2020.03.170","article-title":"MiR-29b-3p cooperates with miR-29c-3p to affect the malignant biological behaviors in T-cell acute lymphoblastic leukemia via TFAP2C\/GPX1 axis","volume":"527","author":"M Zhuang","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"pone.0352501.ref031","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1159\/000527456","article-title":"Extracellular Vesicles Derived from Human Bone Marrow Stem Cells Inhibit Acute Lymphoblastic Leukemia Cell Growth by Inhibiting MAPK Pathway via the miR-29b-3p\/GDF15 Axis","volume":"146","author":"L Zhou","year":"2023","journal-title":"Acta Haematol"},{"issue":"4","key":"pone.0352501.ref032","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.3390\/cells9041044","article-title":"Sorting Mechanisms for MicroRNAs into Extracellular Vesicles and Their Associated Diseases","volume":"9","author":"M Groot","year":"2020","journal-title":"Cells"},{"issue":"18","key":"pone.0352501.ref033","doi-asserted-by":"crossref","first-page":"9046","DOI":"10.1128\/JVI.76.18.9046-9059.2002","article-title":"Ahi-1, a novel gene encoding a modular protein with WD40-repeat and SH3 domains, is targeted by the Ahi-1 and Mis-2 provirus integrations","volume":"76","author":"X Jiang","year":"2002","journal-title":"J Virol"},{"issue":"6","key":"pone.0352501.ref034","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jnci\/djt006","article-title":"Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex","volume":"105","author":"M Chen","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"pone.0352501.ref035","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1182\/blood-2003-11-4026","article-title":"Deregulated expression in Ph+ human leukemias of AHI-1, a gene activated by insertional mutagenesis in mouse models of leukemia","volume":"103","author":"X Jiang","year":"2004","journal-title":"Blood"},{"issue":"4","key":"pone.0352501.ref036","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/hon.3030","article-title":"Prognostic utility of key copy number alterations in T cell acute lymphoblastic leukemia","volume":"40","author":"S Kumari","year":"2022","journal-title":"Hematol Oncol"},{"issue":"11","key":"pone.0352501.ref037","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1084\/jem.20072316","article-title":"AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem\/progenitor cells","volume":"205","author":"LL Zhou","year":"2008","journal-title":"J Exp Med"},{"issue":"13","key":"pone.0352501.ref038","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/pmic.201100553","article-title":"Molecular and structural characterization of the SH3 domain of AHI-1 in regulation of cellular resistance of BCR-ABL(+) chronic myeloid leukemia cells to tyrosine kinase inhibitors","volume":"12","author":"X Liu","year":"2012","journal-title":"Proteomics"},{"key":"pone.0352501.ref039","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.13","article-title":"Progress in RNAi-mediated Molecular Therapy of Acute and Chronic Myeloid Leukemia","volume":"4","author":"B Landry","year":"2015","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"pone.0352501.ref040","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41392-024-01735-1","article-title":"Extracellular vesicles as tools and targets in therapy for diseases","volume":"9","author":"MA Kumar","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"pone.0352501.ref041","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer current: status, challenges and future prospects","volume":"9","author":"L Ma","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"pone.0352501.ref042","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/s12276-023-01050-9","article-title":"MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies","volume":"55","author":"T Kim","year":"2023","journal-title":"Exp Mol Med"},{"issue":"4","key":"pone.0352501.ref043","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s41375-024-02188-9","article-title":"Leukemogenesis occurs in a microenvironment enriched by extracellular microvesicles\/exosomes: recent discoveries and questions to be answered","volume":"38","author":"MZ Ratajczak","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"pone.0352501.ref044","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1182\/asheducation-2016.1.580","article-title":"T-cell acute lymphoblastic leukemia","volume":"2016","author":"EA Raetz","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"pone.0352501.ref045","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"T Terwilliger","year":"2017","journal-title":"Blood Cancer J"},{"issue":"16","key":"pone.0352501.ref046","doi-asserted-by":"crossref","first-page":"5776","DOI":"10.3390\/ijms21165776","article-title":"Philadelphia Chromosome-Positive Leukemia in the Lymphoid Lineage-Similarities and Differences with the Myeloid Lineage and Specific Vulnerabilities","volume":"21","author":"L Komorowski","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"8","key":"pone.0352501.ref047","first-page":"2309","article-title":"Adult Ph-positive acute lymphoblastic leukemia-current concepts in cytogenetic abnormalities and outcomes","volume":"10","author":"T Shi","year":"2020","journal-title":"Am J Cancer Res"},{"issue":"1","key":"pone.0352501.ref048","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41572-024-00525-x","article-title":"Acute lymphoblastic leukaemia","volume":"10","author":"L Pagliaro","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"pone.0352501.ref049","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","article-title":"The genomic landscape of pediatric acute lymphoblastic leukemia","volume":"54","author":"SW Brady","year":"2022","journal-title":"Nat Genet"},{"issue":"1","key":"pone.0352501.ref050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12032-024-02547-7","article-title":"Dual roles of extracellular vesicles in acute lymphoblastic leukemia: implications for disease progression and theranostic strategies","volume":"42","author":"MS Lajevardi","year":"2024","journal-title":"Med Oncol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0352501","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:31:19Z","timestamp":1782322279000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0352501"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Bertolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0352501","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]}}}